NIH Technology Transfer

As of March 11, 2026, this account is no longer active.
Please look for our content on the National Institutes of Health (NIH) page and follow along for the latest news and information from NIH! For NIH Tech Transfer specific news and technology opportunities, please visit our website at techtransfer.nih.gov.

Current diagnostic tests for COVID-19 and other viruses require RNA extraction and analysis of the extracted RNA sample. NIH Inventors have developed a novel, improved sample preparation method that eliminates the need for an RNA extraction step, improving workflow safety and eliminating the need for a BSL-2 testing facility, which lowers cost. Potential commercial applicants of this technology include:
· Improved COVID-19 diagnostic test,
· Improved DNA or RNA-based diagnostic test for additional infectious diseases,
· Safer preparation of patient samples, and
· Reagent kits for biomarker profiles and inherited diseases.

NIH is seeking licensees or collaborators for this technology. Learn more on our website: go.nih.gov/yDGaoxi

Opportunity for Infectious Disease Diagnostic Test That Improves Safety and Lowers Cost | Technology Transfer These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

Licensing/collaboration opportunity for a method to produce large quantities of B-regulatory cells for use in Breg-based therapy against autoimmune diseases.

More information on this opportunity can be found on our website: go.nih.gov/1z94Jh8

Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases Available | Technology Transfer These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease.

If you are interested in licensing and/or collaborating on this potential therapeutic drug for Th17-relevant inflammatory diseases, you can view more information on our website: go.nih.gov/FOe7kq9

Licensing/Collaboration Opportunity for Inflammatory Diseases Therapeutic | Technology Transfer These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

Register to attend a free webinar to learn about a co-development opportunity for a new AI enhanced real-time echocardiography device and method to improve the analysis and quantification of heart related conditions, by automatically extracting predictive biomarkers from an echocardiograph scan. Dr. Sameer Antani, co-inventor, will discuss how this technology can be used to acquire biomarkers that could assist diagnosing a wide range of common cardiac diseases, as well as evaluating cardiac function in patient populations suffering from diseases such as sickle cell disease and other rare diseases.

You can read more about this opportunity and register for the webinar on our website: go.nih.gov/vGHtwzG

Webinar: Real-time AI System for Echocardiography Analysis and Quantification | Technology Transfer These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases' Dr. John O’Shea has been selected as a National Academy of Inventors Fellow. Dr. O’Shea is a leading inventor in the field of cytokine signal transduction, specifically in dissecting the role of the Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) family transcription in immunoregulation. There are now 11 approved JAK inhibitors for multiple forms of arthritis, inflammatory bowel disease, dermatologic disorders, and COVID-19.

The National Academy of Inventors honors individuals as Fellows to recognize that not only are they phenomenal researchers holding prestigious honors and distinctions but are also incredible inventors.

You can read more about Dr. O’Shea’s work and the other NIH inventor selected as an NAI Fellow this year on our website: go.nih.gov/dKup1at

Two NIH Inventors Selected as 2025 National Academy of Inventors Fellows | Technology Transfer These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

NIH National Cancer Institute's Dr. Steven Rosenberg has been selected as a National Academy of Inventors Fellow. Dr. Rosenberg is often regarded as the father of cancer immunotherapy as he began working on immunotherapy in the 1970s when little was known about T lymphocyte function in cancer. He holds an extraordinary 884 patents!

The National Academy of Inventors honors individuals as Fellows to recognize that not only are they phenomenal researchers holding prestigious honors and distinctions but are also incredible inventors.

You can read more about Dr. Rosenberg’s pioneering in the field of immunotherapy and the other NIH inventor selected as an NAI Fellow this year on our website: go.nih.gov/dKup1at

Two NIH Inventors Selected as 2025 National Academy of Inventors Fellows | Technology Transfer These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

In honor of Tech Transfer Professionals Day, we wanted to reshare IAM's recognition of NIH OTT Director Tara Kirby. You can read about the deal that secured her spot on the list of one of the most innovative and influential dealmakers of the year below.

www.techtransfer.nih.gov

In honor of Tech Transfer Professionals Day, we are highlighting Dr. Yogi Prabhu from the National Institute of Allergy and Infectious Diseases (NIAID) Technology Transfer and Intellectual Property Office. Yogi was led to a career in tech transfer after exploring alternative science careers following her postdoctoral research. You can learn more about what attracted Yogi to a career in tech transfer on our website: go.nih.gov/4n3zMQn

Blending Science, Business, and Law: What Attracted Dr. Yogi Prabhu to a Career in Tech Transfer | Technology Transfer These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

Hear from NIH Tech Transfer expert Dr. Michael Salgaller at the MedInvest MedTech, AI & Digital Health Conference being held Dec. 10-11, 2025. More information on NIH's participation can be found: go.nih.gov/owvm0Ix

Attend the MedInvest MedTech, AI & Digital Health Conference to Learn About Licensing and Collaborating with the NIH | Technology Transfer These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

NIH is seeking a licensee for a technology that treats developmental stuttering using FDA-approved iron chelators. This is a greatly underserved market as currently the only method of treating this disorder is through speech therapy. If you are interested in learning more about this opportunity to bring the first oral therapy for developmental stuttering to market, you can find more information on our website: go.nih.gov/aIdVFtR

Licensing Opportunity for the First Therapeutic to Target Developmental Stuttering | Technology Transfer These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.